Mutation of the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene by homologous recombination caused alveolar proteinosis in mice. To further discern the role of GM-CSF in surfactant homeostasis, the synthesis of GM-CSF was directed to the respiratory epithelium of GM-CSF-null mutant mice (GM Ϫ 
Introduction
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a 23-kD glycoprotein (1) encoded by a single gene containing four exons spanning 2.4 kb of the mouse genome (2) . While GM-CSF was initially isolated from conditioned media from pulmonary cells, GM-CSF is expressed in a variety of hematopoietic cell types and nonhematopoietic cells and cell lines (3) (4) (5) (6) (7) (8) . GM-CSF has potent hematopoietic regulatory properties and was named for its ability to stimulate proliferation and differentiation of granulocyte and macrophage precursor cells in soft agar culture (4) . GM-CSF stimulates proliferation and activation of mature granulocytes and macrophages and induces migration and proliferation of endothelial cells (3, 4, (9) (10) (11) . Development of GM-CSF-dependent hematopoietic precursor cell lines provided further evidence that established GM-CSF as a regulator of hematopoietic cell proliferation and differentiation (12, 13) .
Extensive animal and human studies demonstrated that GM-CSF is a potent hematopoietic growth factor (8) . Recombinant murine GM-CSF administered intravenously increased peripheral blood cell populations. Activated peritoneal macrophages, neutrophils, and eosinophils increased after peritoneal injection of GM-CSF without altering blood or bone marrow populations of these cells. Transgenic mice expressing GM-CSF under control of the Moloney murine leukemia virus promoter displayed a phenotype consistent with that of wildtype mice injected intraperitoneally with recombinant GM-CSF. Infusion of recombinant human GM-CSF stimulated hematopoiesis in primates (14) . Recombinant human GM-CSF has been used after chemotherapy treatment to counteract bone marrow depression (15) .
GM-CSF-null mutant mice (GM Ϫ / Ϫ ) were generated by gene targeting (16) (17) (18) . However, hematopoietic development and function were not disturbed in the GM Ϫ / Ϫ mice. Surprisingly, GM Ϫ / Ϫ animals developed pulmonary disease characteristic of pulmonary alveolar proteinosis (PAP) 1 associated with markedly increased concentrations of surfactant proteins and phospholipids in the alveolar spaces. Pulmonary surfactant is a heterogeneous mixture of phospholipids and associated surfactant proteins-A, -B, -C, and -D (SP-A, SP-B, SP-C, and SP-D) which are synthesized and secreted by pulmonary type II epithelial cells (for review see reference 19) . Clearance of surfactant is mediated primarily by type II cells, which take up ‫ف‬ 80% of surfactant phospholipids and proteins for recycling or degradation; the remainder is cleared by alveolar macrophages (20).
The accumulation of surfactant in the lungs of GM Ϫ / Ϫ mice supports the hypothesis that GM-CSF is required for regulation of pulmonary surfactant homeostasis, perhaps mediating surfactant clearance by alveolar macrophages and alveolar type II epithelial cells. The recent finding that respiratory epithelial cells synthesize GM-CSF is consistent with the hypothesis that GM-CSF plays an important role in surfactant metabolism. In the present work, GM-CSF was selectively expressed in type II epithelial cells of the GM Ϫ / Ϫ mouse, correcting the alveolar proteinosis associated with this animal model.
Methods

Construction of the SP-C-GM-CSF chimeric gene.
Cloning vector p3.7-tpA, comprised of the human SP-C promoter region, nucleotides Ϫ 3683 to ϩ 18 (3.7SP-C) (21, 22) , followed by a multiple cloning site, SV40 small t-intron, and polyadenylation signal, was used to construct the chimeric gene in a pUC18 plasmid, as described previously (23). The coding region of mouse GM-CSF cDNA, bp 174-620, was isolated from pMFGmuGM-CSF (10) . Ends were modified with addition of EcoRI linkers and inserted into the EcoRI site of p3.7-tpA to generate p3.7GM-tpA.
Production of transgenic mice. The SP-C-GM-CSF chimeric gene was excised from the parental plasmid p3.7GM-tpA by NdeI/NcoI digestion and purified by agarose gel electrophoresis in the absence of ethidium bromide. The DNA was recovered using Qiaex Gel extraction kit (QIAGEN Inc., Chatsworth, CA) and dialyzed in 5 mM TrisHCl, pH 7.5, and 0.1 mM EDTA for 36 h. Donor eggs from FVB/N mice (GM ϩ / ϩ ) were prepared for pronuclear injection. Sperm was obtained from GM-CSF-null mutant mice (GM Ϫ / Ϫ ), described previously (16) . Tail DNA was digested with BamHI and Southern blotted, using the EcoRI fragment of GM-CSF cDNA from p3.7GM-tpA to probe for wild-type (9.2 kb), null mutant (4.1 kb), and SP-C-GM-CSF-transgenic (0.5 kb) alleles. SP-C-GM-CSF transgenic founders were back-crossed with GM Ϫ / Ϫ mice to generate pups that were homozygous GM Ϫ / Ϫ and heterozygous for the SP-C-GM-CSF transgene (GM Ϫ / Ϫ , SP-C-GM ϩ ). GM Ϫ / Ϫ , GM ϩ / ϩ mice, and GM ϩ / Ϫ littermates were used as age-matched controls as indicated.
Processing and staining of tissues for histopathology. Lungs were inflation fixed with 4% paraformaldehyde/phosphate-buffered saline (PBS), pH 7.4, for 24 h, as described previously (24) . Tissue was then washed in PBS, dehydrated in a series of alcohols, and embedded in paraffin. Hematoxylin and eosin staining was used for histological analysis of paraffin sections.
Immunohistochemistry. Paraffin sections of 5 m were used to stain for surfactant protein. Anti-SP-B (28031) is a rabbit anti-bovine polyclonal antibody that recognizes mature SP-B (25) . Anti-SP-B was detected using a secondary antibody and detection system (Vectastain ABC anti-rabbit immunohistochemical horseradish peroxidase kit; Vector Labs, Inc., Burlingame, CA). Tissues were counterstained with hematoxylin and eosin.
RNA isolation. RNA was isolated by a modification of the guanidinium-thiocyanate method described by Chomczynski and Sacchi (26) . Briefly, tissues were homogenized in guanidinium-thiocyanate.
A series of phenol-chloroform extractions was followed by precipitation in isopropanol as described in RNA isolation protocol package insert for Phase-Lock Gel IIA Heavy Tubes (5 Prime-3 Prime, Inc., Boulder, CO). S1 nuclease protection analysis. Total lung RNA (2 g) was hybridized in solution at 55 Њ C for 18 h with an excess of 32 P-end-labeled linearized probes in 400 mM NaCl, 2 mM EDTA, 40 mM Pipes, pH 6.6, and 80% formamide. Each sample was treated with S1 nuclease at 37 Њ C for 1 h in 100 mM NaCl, 15 mM NaOAc, pH 4.5, 2.5 mM ZnSO 4 , 25 ng denatured salmon sperm DNA, with 110 U S1 nuclease (GIBCO-BRL, Gaithersburg, MD). Protected fragments were resolved on a 6% polyacrylamide/8 M urea gel and visualized by autoradiography. Plasmids containing probe sequences for SP-A, SP-B, SP-C, and L32 were kindly provided by Dr. Cindy Bachurski (Children's Hospital Medical Center, Cincinnati, OH) (16) .
Peritoneal wash, blood collection, and cell counts. Mice were anesthetized by inhalation of methoxyflurane. 2 ml of PBS (pH 7.4) was injected into the peritoneal cavity using a 25-gauge needle. The abdomen was massaged gently and carefully opened to recover the fluid. Volume, color, and turbidity of each sample was noted to assure that ascites were not present in animals tested. Each sample was stored on ice until manual cell counts were performed. Mice were killed by exsanguination from the posterior vena cava. Blood was placed in microtubes containing EDTA for cell counts or allowed to clot for serum collection. Manual white blood cell and differential cell counts were performed. Cell counts were performed on bronchoalveolar lavage (BAL) fluid by flow cytometry using MAC-1 and Thy-1 antibodies to identify macrophages and T cells, respectively (Pharmingen, San Diego, CA).
BAL studies. Mice were anesthetized with pentobarbital injected intraperitoneally, and BAL was performed three times with 1-ml aliquots of PBS which were pooled and the volume measured. Cells were removed by centrifugation at 6,300 g for 10 min, and aliquots were stored at Ϫ 20 Њ C until analysis. SP-B was measured by ELISA as previously described (27) . SP-A was measured using ELISA rabbit anti-mouse SP-A antiserum. GM-CSF was measured using GM-CSF Minikit ELISA (Endogen, Inc., Boston, MA). Horseradish peroxidase-Streptavidin (Zymed Laboratories, Inc., South San Francisco, CA) was diluted to 1:8,000. Substrate was DAKO TMB one-step Substrate System (Dako Corp., Carpinteria, CA). The lower limits of detection with this system are Ͻ 5-35 pg/ml, thus, any samples falling within this range or below were reported as not detectable. No samples reported as not detectable were Ͼ 12 pg/ml. All samples Ͼ 200 pg/ml were diluted and repeated. To assay saturated phosphatidylcholine (Sat PC) in BAL fluid, mouse lungs were lavaged and Sat PC was determined as described previously (27a).
Results
Promoter sequences (3.7SP-C) from the human SP-C gene, nucleotides Ϫ 3683 to ϩ 18, were used to construct a chimeric gene directing expression of mouse GM-CSF cDNA in the respiratory lung epithelium of wild-type and GM Ϫ / Ϫ mice (Fig.  1, A-C ) . Ova from GM ϩ / ϩ females were fertilized with sperm from GM Ϫ / Ϫ males. At the pronuclear stage of development, the SP-C-GM-CSF chimeric gene was injected into the ova, which were transferred to pseudopregnant foster mothers. Founders were screened by Southern blotting of tail DNA digested with BamHI, using a mouse cDNA probe (Fig. 2) . Genotypes GM ϩ / Ϫ , SP-C-GM Ϫ or GM ϩ / Ϫ , SP-C-GM ϩ were determined by the presence of 9.2-, 4.1-, or 0.5-kb bands for White blood cell differentials were performed on peripheral blood smears from GMϪ/Ϫ, SP-C-GMϩ; GMϪ/Ϫ, SP-C-GMϪ; and GMϩ/Ϫ, SP-C-GMϪ animals. Results show percentage of monocytes, lymphocytes, and granulocytes counted; meanϮSD; n ϭ 5 individuals of each genotype.
wild-type GM-CSF allele, GM-CSF-null allele, and SP-C-GM-CSF transgene, respectively. Three distinct GMϩ/Ϫ, SP-C-GMϩ transgenic mice founders were backcrossed to GMϪ/Ϫ mice to obtain GMϪ/Ϫ, SP-C-GMϩ pups. One founder mouse (F16) failed to breed and was moribund at 4 mo; histology of lungs from this animal demonstrated marked pulmonary infiltration with alveolar macrophages and no alveolar proteinosis. Two other GMϩ/Ϫ, SP-C-GMϩ mice, designated F48 and F59, were used to establish separate lines. Genotypes of offspring were as expected from Mendelian inheritance, indicating that the transgene had inserted into an autosomal locus in each line. Litters were of expected sizes, and pups were healthy with normal growth and development. Mice from each line have been bred to the F4 generation and are Ͼ 9 mo old at present. Founder mice are now Ͼ 11 mo old and are apparently healthy.
There were no apparent systemic effects of GM-CSF, and effects of the transgene were restricted to the lung. Peripheral blood counts were similar in GMϪ/Ϫ, SP-C-GMϩ; GMϪ/Ϫ, SP-C-GMϪ; and GMϩ/Ϫ, SP-C-GMϪ mice (Table I) . Likewise, cell counts of peritoneal washes from GMϪ/Ϫ, SP-C-GMϩ; GMϪ/Ϫ, SP-C-GMϪ; and GMϩ/Ϫ, SP-C-GMϪ mice were indistinguishable, 5.0Ϯ1.8 (n ϭ 3), 4.4Ϯ2.4 (n ϭ 5), and 3.3Ϯ0.3 (n ϭ 4) ϫ 10 6 cells recovered meanϮSD, respectively. Values for peripheral blood and peritoneal wash cell counts were within ranges established in the literature (28, 29) . Histopathologies of spleens from wild-type, GMϪ/Ϫ, and bitransgenic mice were identical. The numbers of MAC-1-reactive cells were increased in BAL fluid from the GMϪ/Ϫ, SP-C-GMϩ mice compared with wild-type and GMϪ/Ϫ mice (lacking the SP-C-GM transgene) as assessed by flow cytometry, a finding consistent with the increased numbers of alveolar macrophages observed histologically (Fig. 3, A-D) . Numbers of cells collected by BAL were increased similarly in GMϩ/Ϫ, SP-C-GMϩ and GMϪ/Ϫ, SP-C-GMϩ lines and were not different in mice from lines 48 or 59. BAL cell counts were 0.074Ϯ0.02 ϫ 10 6 meanϮSD (n ϭ 4) in GMϩ/Ϫ mice compared with 0.72Ϯ0.3 ϫ 10 6 (n ϭ 4) in line 48 and 0.79Ϯ0.32 ϫ 10 6 (n ϭ 4) in line 59 of the GMϩ/Ϫ, SP-C-GMϩ mice. Similarly, cell numbers were 0.47 ϫ 10 6 (line 48) and 1.1 ϫ 10 6 (line 59) n ϭ 2 each in the GMϪ/Ϫ, SP-C-GMϩ mice.
Proteinaceous accumulations in the alveolar spaces were not detected in lungs from GMϪ/Ϫ, SP-C-GMϩ and GMϩ/Ϫ, SP-C-GMϪ (Fig. 4, C and E) , or GMϩ/ϩ mice (16) , in sharp contrast to lungs from GMϪ/Ϫ, SP-C-GMϪ littermates, wherein eosinophilic material filled the alveolar spaces in all lobes of the lungs, that was intensely stained by SP-B antibody (Fig. 4, A and B) . The intensity of anti-SP-B staining of type II cells in GMϪ/Ϫ, SP-C-GMϩ and GMϩ/Ϫ, SP-C-GMϪ mice (Fig. 4, D and F) was similar to that of GMϩ/ϩ wild-type mice D and F) . Intense staining of alveolar material was noted in the GMϪ/Ϫ, SP-C-GMϪ lung (B), corresponding to the proteinaceous infiltrates noted by hematoxylin and eosin staining (A). Lungs from GMϩ/Ϫ, SP-C-GMϪ mice stained with hematoxylin and eosin (E) and anti-SP-B (F) were indistinguishable from those of wild-type GMϩ/ϩ animals (not shown). Sections are representative of offspring from two separate founder SP-C-GM-CSF lines, assessing n ϭ 3 mice per line.
Discussion
The local expression of murine GM-CSF in respiratory epithelial cells of lungs of transgenic mice corrected the alveolar proteinosis and lymphocytic infiltrates characteristic of the lungs of GMϪ/Ϫ mutant mice. The accumulation of surfactant proteins and phospholipids was resolved in the absence of detectable systemic effects of the transgene, supporting the hypothesis that the local production of GM-CSF by lung cells influenced surfactant homeostasis mediated by respiratory epithelial cells and alveolar macrophages.
The marked accumulations of surfactant in GMϪ/Ϫ mice and the resolution of the alveolar proteinosis in the GMϪ/Ϫ, Figure 5 . GM-CSF and surfactant proteins in GMϪ/Ϫ and GMϪ/Ϫ, SP-C-GMϩ mice. SP-A, SP-B, and GM-CSF were measured in BAL fluid from GMϪ/Ϫ, SP-C-GMϪ; GMϪ/Ϫ, SP-C-GMϩ; and GMϩ/Ϫ, SP-C-GMϪ mice (n Ն 4). SP-A and SP-B levels in GMϪ/Ϫ, SP-C-GMϪ mice were Ն 10-fold higher than in GMϩ/Ϫ, SP-C-GMϪ mice; the latter were also within the range of healthy GMϩ/ϩ mice (data not shown). GM-CSF was not detectable in BAL from either GMϪ/Ϫ, SP-C-GMϪ or GMϩ/Ϫ, SP-C-GMϪ mice. SP-A and SP-B in BAL collected from GMϪ/Ϫ, SP-C-GMϩ mice were within the ranges found in GMϩ/Ϫ, SP-C-GMϪ and GMϩ/ϩ mice. Values are meanϮSD, n Ն 4 per group. ND, not detectable. Figure 6 . S1-Nuclease assay for SP-A, -B, and -C mRNA. SP-A, SP-B, and SP-C mRNAs were assessed in lungs from GMϪ/Ϫ, SP-C-GMϪ; GMϩ/Ϫ, SP-C-GMϪ; and GMϪ/Ϫ, SP-C-GMϩ mice. Sizes of protected fragments are indicated on the right in nucleotides (nt). When normalized for loading using ribosomal L32 surfactant protein mRNA were not different in the various lines tested. There was no statistically significant difference found between the genotypic groups. n Ն 4 by ANOVA.
SP-C-GMϩ mice occurred independently of changes in surfactant protein mRNAs or intracellular SP-B staining. These findings suggest that altered surfactant metabolism, reuptake, or catabolism, rather than increased production of surfactant components, are involved in the PAP in GMϪ/Ϫ mice. The recent findings that surfactant phospholipid and 125 I-SP-A clearance was markedly decreased in the GMϪ/Ϫ mice and that rates of phospholipid synthesis and secretion were relatively unchanged provide further support for the role of GM-CSF in surfactant clearance pathways (27a). On the other hand, surfactant synthesis and surfactant protein RNA content were not altered in the GMϪ/Ϫ mice in spite of the marked accumulation of surfactant proteins and lipids. Thus, counterregulatory mechanisms failed to decrease steady state surfactant synthesis that might have ameliorated abnormalities of surfactant accumulation in the PAP mice. These findings may reflect disordered counterregulatory mechanisms or that steady state surfactant concentrations are maintained primarily by the regulation of recycling and catabolism rather than by pathways that modulate surfactant biosynthesis.
In the present study, the human SP-C promoter (3.7SP-C) was used to direct synthesis of GM-CSF to alveolar type II cells and to distal bronchiolar epithelial cells in the lung. The h3.7SP-C promoter has been used extensively to express genes in a cell-specific manner in the lungs of transgenic mice. Expression of the exogenous cDNAs or minigenes is consistently restricted to type II epithelial cells and distal bronchiolar epithelial cells (for review see reference 30). We were unable to detect SP-C-GM-CSF mRNA by either RT-PCR or Northern blot analysis, even though GM-CSF protein was readily detected in the BAL fluid of the SP-C-GMϩ mice. The endogenous GM-CSF mRNA is frequently undetectable in biological samples, likely due to its short biological half-life (3). Instability of the GM-CSF mRNA may account for difficulty in detecting the transgenic GM-CSF mRNA. Nevertheless, restriction of pathological findings to the lung, increased concentrations of GM-CSF in the BAL fluid, and absence of extrapulmonary effects seen in the GMϪ/Ϫ, SP-C-GMϩ mice suggest that the SP-C-GM-CSF mRNA is produced in the lung and is translated into biologically active GM-CSF. The finding that GM-CSF mRNA was not readily detected in the transgenic mice might be related to loss of transgenic mice expressing high levels of GM-CSF mRNA, although we did not observe increased perinatal death of SP-C-GM founder mice. GM-CSF was readily detected in BAL but not in peripheral blood from the bitransgenic mice, providing further support for the concept that GM-CSF is acting locally, rather than peripherally, to correct the alveolar proteinosis in the GMϪ/Ϫ model. Peripheral blood leukocytes, splenic histology, and the lack of changes in peritoneal macrophages support the likelihood that the effects of the SP-C-GM-CSF transgene were not mediated by extrapulmonary GM-CSF. In contrast, transgenic mice expressing GM-CSF under control of the Moloney murine leukemia virus promoter developed abnormalities of tissue macrophage cell populations that were not observed in the present studies (8) . It remains possible, however, that the local production of GM-CSF in the lung influences cells of granulocytic and monocytic cell lineages at distant sites and that the production of GM-CSF in the lung has provided signals necessary for appropriate granulocytic-monocytic maturation in other organs that corrects the abnormalities of surfactant homeostasis seen in the lung.
While alveolar macrophage numbers were not substantially altered in the lungs of GMϪ/Ϫ mice (16), macrophages became increasingly foamy and laden with lipids and surfactant proteins. Marked perivascular and peribronchiolar lymphocytic infiltration were also noted in the lungs of GMϪ/Ϫ mice. Both of these histologic features of the GMϪ/Ϫ mice were resolved in the bitransgenic mice expressing GM-CSF in the lung. The mechanisms involved in the resolution of PAP and restoration of macrophage morphology have not been clarified in the present studies. While morphology of the macrophages appears to be normal in the bitransgenic mice, the numbers of alveolar macrophages isolated in the lungs by alveolar lavage were increased in the GMϪ/Ϫ, SP-C-GMϩ mice. These increased numbers of alveolar macrophages may contribute to more rapid clearance or catabolism in the corrected bitransgenic mice. Immunohistochemical staining for proliferating cell nuclear antigen was observed in a small percentage of macrophages in both wild-type and corrected mice, suggesting that local proliferation of macrophages may occur in the lungs of the GMϪ/Ϫ mice (data not shown). Since GM-CSF exerts proliferative, chemoattractant, and activating effects on alveo- Figure 7 . Phospholipid analysis of BAL from GM-deficient and -replete mice. Sat PC content in BAL from GMϪ/Ϫ, SP-C-GMϪ mice was Ͼ 10 fold higher than in GMϪ/Ϫ, SP-C-GMϩ or GMϩ/Ϫ, SP-C-GMϪ mice. Sat PC content in GMϪ/Ϫ, SP-C-GMϩ mice did not differ significantly from GMϩ/Ϫ, SP-C-GMϪ or GMϩ/ϩ mice (not shown). Values are meanϮSD, n Ն 4 per group. lar macrophages, the local proliferation of macrophages may not be the only mechanism resulting in the increased numbers and activity of alveolar macrophages in the corrected transgenic mice.
The present findings support a model by which local production of GM-CSF in the lung corrects PAP in the GMϪ/Ϫ mouse. However, the sites of expression and regulatory role of GM-CSF in normal lung physiology have not been clarified. While rat type II epithelial cells express GM-CSF in vitro (7), the normal in vivo sites and levels of GM-CSF protein or receptors in the lung remain to be elucidated. The relative instabilities of GM-CSF mRNA and protein complicate the analysis of potential signaling pathways that might be involved in regulation of surfactant homeostasis by GM-CSF and its receptors in the normal lung in vivo. It is therefore unclear whether surfactant homeostasis in the wild-type mouse and the abnormalities of surfactant homeostasis seen in GM-CSF mouse are mediated by interactions of GM-CSF with alveolar macrophages, type II epithelial cells, or both cell types.
Pulmonary alveolar proteinosis is a relatively uncommon, clinical syndrome with pathological features of surfactant lipid and protein accumulation similar to the findings of the GMϪ/Ϫ mouse. Pulmonary alveolar proteinosis has been associated with metabolic disease and acquired disorders of the hematopoietic systems (31) . The present findings that the local production of GM-CSF corrects abnormalities of surfactant homeostasis in the bitransgenic GMϪ/Ϫ, SP-C-GMϩ mice support the important role of GM-CSF in surfactant homeostasis and the hypothesis that abnormalities of GM-CSF or its receptors may be involved in the pathogenesis of PAP in humans.
